Condition (MeSH)
Osteosclerosis
ClinicalTrials.gov lists 35 trials for Osteosclerosis or a narrower condition beneath it. Bellicum Pharmaceuticals has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 more section with rows
11 of the 35 trials are tagged with Osteosclerosis itself; the rest are tagged with a narrower condition beneath it.
When did Osteosclerosis trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 2 |
| 2016 | 2 |
| 2015 | 1 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 35 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Osteosclerosis trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 4 |
| Phase 2 | 7 |
| Phase 2/3 | 3 |
| Phase 3 | 2 |
| Phase 4 | 1 |
| Not applicable | 8 |
| Observational | 8 |
| Expanded access | 1 |
How many Osteosclerosis trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 6 |
| Active, not recruiting | 3 |
| Completed | 15 |
| Terminated | 6 |
| No longer available | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Osteosclerosis trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Bellicum Pharmaceuticals | 2 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| FDA Office of Orphan Products Development | 1 |
Which drugs are being tested for Osteosclerosis? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 2 |
| Busulfan | 2 |
| Rimiducid | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Alemtuzumab s.c. | 3 |
| SQ Fludarabine | 3 |
| Stem Cell Transplantation | 3 |
| Low Level Laser Therapy | 2 |
| BPX-501 T cells | 2 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Osteosclerosis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Fever | 32 | 1 |
| Graft vs. Host disease | 9 | 1 |
| HHV-6 Reactivation | 9 | 1 |
| Thrombotic microangiopathy | 8 | 2 |
| Pyrexia | 7 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Osteosclerosis? (12)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Sclerotic vertebral metastases: pain palliation using percutaneous image-guided cryoablation. | Cardiovascular and interventional radiology | 2011 | Yes |
| Sclerosing bone dysplasias: review and differentiation from other causes of osteosclerosis. | Radiographics : a review publication of the Radiological Society of North America, Inc | 2011 | Yes |
| Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research | 2008 | Yes |
| Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease. | The British journal of oral & maxillofacial surgery | 2014 | No |
| Sclerostin: current knowledge and future perspectives. | Calcified tissue international | 2010 | No |
Showing 5 of 12 publications.
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.